US 10,889,545 B2
Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt
Aeri Kim, Seoul (KR); and Kwan Hyung Cho, Busan (KR)
Assigned to Daewoong Pharmaceutical Co., Ltd., Gyeonggi-do (KR)
Filed by Daewoong Pharmaceutical Co., Ltd., Gyeonggi-do (KR)
Filed on Dec. 18, 2019, as Appl. No. 16/718,300.
Application 16/718,300 is a division of application No. 16/411,270, filed on May 14, 2019.
Application 16/411,270 is a division of application No. 16/073,359, granted, now 10,336,695, previously published as PCT/KR2017/002914, filed on Mar. 17, 2017.
Claims priority of application No. 10-2016-0036080 (KR), filed on Mar. 25, 2016.
Prior Publication US 2020/0123106 A1, Apr. 23, 2020
Int. Cl. C07D 207/48 (2006.01); A61K 31/40 (2006.01)
CPC C07D 207/48 (2013.01) [A61K 31/40 (2013.01); C07B 2200/13 (2013.01)] 4 Claims
 
1. A crystalline form I of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine fumarate having peaks at diffraction angles (2θ±0.2°) of 7.9°, 11.9° and 24.0° in an X-ray powder diffraction pattern.